Health and Shopping Blog

Long time before urologists recognized the physical nature of impotence, treatments generally fell into three categories-aphrodisiacs, and mechanical treatments.

Aphrodisiacs

Oysters, lobsters, eggs, and spices are examples. Spanish Fly, a substance made by grinding the wings of certain beetles, was a favorite of that party animal, the Marquis de Sade. It is illegal in the United States both because of the unproven nature of its effectiveness and a tendency to cause seizures or death. Many of these substances actually do nothing more than irritate the genital organs. The user interprets this irritation as increased sensitivity, thereby giving the impression of increased performance. Rhinoceros horn has been used (unsuccessfully) for so long that its name has become synonymous with sexual arousal. Unfortunately, its popularity has led to such widespread slaughter of the animals that they face extinction. Ancient Egyptians believed eating crocodile penises increased virility. Anyone capable of eating a crocodile’s penis probably didn’t need any more help proving his manhood.

Surgery/Transplants

The Malleus Maleficarum was a guide to witchcraft during that era that asserted witch’s spells caused impotence. The idea of using animal testes to treat impotence began in the Middle Ages, when a standard treatment for “the male malady” was to place the testicles of a cock under the bed. Another option was eating the rooster’s testes. You could guess that putting them under the bed was much more popular. This was a major reason witch-hunting became so widespread. French physiologist Charles Edouard Brown-Sequard injected himself in the 1880s with an extract from the testicles of dogs that he claimed made him smarter, stronger, and more virile. After ten injections, he reported improved erections, as well as a stronger jet of urine and “power of defecation.” He made no claims about the effect this had on the dogs. His “Elixir of Life” became an instant best-seller. Its 1889 launch rivaled that of cheap Levitra, even without a famous spokesman.

Mechanical

Hot metal rods inserted into the urethra during medieval times failed to revive erections. No one wanted a second treatment, so failures went unreported. Many types of splints have been used, including hollowed-out antlers and horns. Encouraged by finding the penis bone (baculum) in some animals, early surgeons placed rib cartilage into the penis. Although these initial attempts failed, penile prostheses have more recently proven particularly reliable.

Perhaps I am growing cynical, but every time I see a new piece of research only lasting one or two years, I wonder why it stopped early. If you have a specific hypothesis, evidence for or against should be apparent fairly quickly. Anyway, the longer a trial goes on, the more difficult it gets to distinguish between potential causes and their effects. So when one or two participants develop a heart condition or get depressed, is this a side effect of the medication under test or a coincidence? But no-one is systematically collecting longitudinal data. This is very convenient for the manufacturers which might have to pull a medication from the market if adverse evidence emerged.

The final thought has to be that if you are unlucky enough to suffer from insomnia, take ambien as directed by your doctor and work intensively with a therapist or counsellor. The combination is the best chance of avoiding long-term problems.

The study shows that most of the group found the insomnia growing steadily more pronounced as the years passed. You might wonder why they were not all given ambien or an equivalent. The answer, of course, is that they were and to excellent short-term effect. Thus, even though ambien and other sleeping pills produced the promised sleep artificially, the majority of participants could not recapture the natural sleeping patterns of their youth. Curiously, women were more at risk of insomnia patterns stabilising and expanding. More worrying was that about 35% of those who had episodes of insomnia lasting more than two weeks subsequently suffered a major depressive disorder. The study concludes that insomnia is persistent and increases the risk of depressive conditions.

American College of Cardiology released some clinical data from the Phase III trials for their proposed competitor to acomplia (rimonabant). This new medication, still going by its generic name of taranabant, targets the same cannabinoid system as acomplia. It is therefore interesting to compare results since, if it gains regulatory approval, it will be a direct competitor to acomplia.

The randomised, double-blind and placebo-controlled trials recruited more than eight hundred participants who all had at least BMI 27. Merck & Co disclosed the preliminary results calculated at the end of year one of what is intended as a two year trial. In conjunction with a diet and exercises, 28% of those taking a 2mg dose of taranabant lost more than 10% of their body weight, while 57% lost 5% of their body weight. Almost 8% of those on placebo also lost 10% of their body weight through diet and exercise alone. In terms of averages, participants taking a 2mg dose of taranabant lost 14.5 pounds compared to 5.7 pounds on placebo. Depending on how you view these things, this could be viewed as a failure because Merck & Co announced in advance that it was aiming for a minimum 5% body weight loss in all participants taking their medication.

In 2004, Acomplia’s results were that 32% on Acomplia lost more than 10% of their body weight while 62.5% lost more than 5% of their body weight. But these results were obtained at the higher dosage of 20mg as opposed to 2mg taranabant. The reason of this difference in the dosage levels is that acomplia is a CB1 receptor antagonist that blocks endogenous cannabinoid binding to neuronal CB1 receptors, while taranabant acts as a selective cannabinoid-1 receptor inverse agonist, binding to CB1 receptors. I am glad we have got that clear.

Merck & Co tested higher doses of 4mg and 6mg but admitted problems with psychiatric side effects. It confirmed that taranabant would probably only be brought to the market at the lowest 2mg dose. Because the FDA has already expressed concern about similar side effects in acomplia, the Merck trials looked more specifically for evidence of the effects.

Nevertheless, this must be placed in a proper context. rimonabant has, of course, been available on prescription in Europe for two years and there is no emerging evidence of problems sufficiently serious to justify withdrawing approval. Indeed, it has just been given a further level of approval in the UK. As its effects are better understood, the reported side effects may be better controlled.

There has been a wealth of research into what causes pain. Pain shows that something inside your organism is not right. Researchers can describe in detail how the sensation is transmitted from its source to the brain so we become aware of the problem and can take action to treat it. Unfortunately, despite our better understanding of what it is, actually relieving the pain remains a challenge. If you aren’t dealing with fatal injuries, nothing extreme comes out. During this time, the pain management choices for doctors focus on the various side effects of the medications, the interactions between medications, etc. If the pain becomes more acute due to a terminal condition, the issues of addiction and, to some extent, adverse side effects are less relevant. The cause may be a physical injury or a disease may affect the way it works. Consequently, the pain may be caused by the damage to the nervous system itself or the system may be sending out general distress symptoms or, in some cases, false pain messages. Physical injuries to the nervous system are very difficult to treat because nerve tissue does not easily regenerate. In other cases, researchers do not properly understand why an apparently undamaged system may malfunction. Because the system that transmits and controls pain sensations may be damaged or not working properly, people often react to treatment in a wide variety of unpredictable ways. For the same reason, many prove more vulnerable than usual to adverse side effects. But the consequences of not providing effective pain relief can be serious.

But ultram is an atypical opioid and its ability to relieve pain of all kinds makes it one of the first-response medications for the treatment of neuropathic pain. Doctors must, of course, take care to avoid adverse interactions with other medications, particularly the two classes of antidepressants. The other most common problem is that anyone with a history of seizures or who is being treated with medications that lower the seizure threshold may be at an increased risk of seizures if they are taking ultram. However, ultram is generally preferred in cases of neuropathic pain because there are fewer problems of dependence so long as people use the medication as prescribed. One of the main difficulties in treating neuropathic pain is that the usual opioid analgesics do not work well. Consequently, it can take longer for the medication to reach a stable and effective level in the blood stream. During the slow build up of the drug, people can become discouraged and either want to switch to another drug thought better or discontinue use of the immediate drug. In clinical trials of the opioids, more than a quarter of participants withdrew because of the physical and psychological side effects. This is unfortunate because it usually takes between four and six weeks for doctors to be able to assess the effectiveness of the chosen opioid. In other words, the balance of advantages against disadvantages usually supports the use of ultram for the treatment of neuropathic pain.

Acomplia allows you to achieve the best results only if you combine it with diet and exercises. There is a simple explanation for this. People who are sufficiently motivated will lose weight if they reduce their calorie intake below their normal daily requirement and increase their metabolic rate through exercise. This forces the body to burn fat as stored energy to fill the gap.

The answer depends on the precise effect that acomplia has. This medication is specifically designed to help people feel less hungry. If you feel hungry, that means, that it’s good time to eat. Thus, if people feel only slightly hungry, they will naturally eat less leading to two opposing statements:

Acomplia should therefore not be seen as a weight reduction medication.

There is another simple explanation. It is an application of the placebo effect. When people believe strongly enough that a medication is effective, it will produce the relevant healing effect. Even though a tablet is actually chemically inert, it can heal in the right context. More importantly, the placebo effect amplifies the therapeutic effect of all real medications. So back to the question of why anyone should use acomplia.

Acomplia should therefore be seen as a weight reduction medication.

Both statements are true consequences. Acomplia is not in itself a “fat buster”. The active chemical ingredients do not circulate through the body via the blood stream metaphorically killing fat cells whenever they find them. It is only a psychological prop to help people maintain their motivation to diet. The body will lose weight naturally if people consume more energy than they take in. If people feel less hungry, this is easier to achieve. Now let us go back to the idea of a placebo making a drug more effective. If everyone believes that acomplia is a fat buster, then it is more likely that people will lose more weight using it.

The study focussed on many adult Scottish participants using the General Health Questionnaire. This research depended on many parameters, such as gender, habits etc. The strongest effect was obtained through engaging in a sport, but there were also good results from gardening and other hobby activities involving physical exercise. Even twenty minutes per week had a good effect on mood.

Thus, whether by accident or design, the linkage between acomplia and physical exercise is genuinely valuable. This article is not, of course, suggesting that physical activity will be a guaranteed cure for any looming depression. But whether you exercise to lose weight or to improve your mood, acomplia with exercise is obviously going to be better than acomplia without exercise.

You can see many sides of cases and principles in dispute bubble up as the injured seek justice. One of the most contentious of the current issues in the United States is the idea of pre-emption. The justification is that the Federal Government has delegated the task of regulating the safety of medications and medical devices to the Food and Drug Administration (FDA). The courts therefore do not have the expertise or the right to second-guess the Federal body.

So, here we comes company which was decided by the 3rd U.S. Circuit Court of Appeals in tandem with Colacicco v. Apotex Inc. The plaintiffs allege fault because the manufacturers of zoloft and paxil failed to give adequate warnings. Both are Selective Serotonin Reuptake Inhibitors (SSRIs) used to treat depression. Patients taking either zoloft or paxil committed suicide. Although there is a black box notice that warns of the risk to some extent, the FDA refused wording in a stronger and more explicit form. The cases brought before the state courts of Pennsylvania and New Jersey reached opposite conclusions. On appeal, it was decided that state laws do pre-empt the right to claim that there was no adequate warning of the risk of suicide.

Whether the FDA should or should not enforce a more strict labelling system has been the subject of debate for some years. The SSRIs including zoloft are associated with changes in mood, particularly among the young. Now, in one sense, that is exactly what a pharmaceutical company making an antidepressant would want to hear.

This is two-edged stick. Also published this month in the Canadian Medical Association Journal is research into the consequences of the warning published by Health Canada that there was an increased risk among younger patients taking SSRIs including zoloft. In the two years after the warning, there was a 25% increase in the number of suicides in Manitoba. Two further facts may be stated: there was a significant reduction in the number of younger patients brought forward for treatment, and a 14% drop in the number of prescriptions written for patients under the age of eighteen years.

The European research only examined the evidence as it affected people under the age of 18 years. We do not know how adults responded to the warning on either side of the Canadian/American border. But Health Canada and the FDA should take greater care in their warnings. Information has no use if you are not told how to use it effectively. It seems that in America, the courts are not willing to allow themselves to be used to penalise the manufacturers if the FDA gets the warnings wrong. I wonder when we can expect research along the Canadian lines to examine the suicide rates in America before and after the FDA’s warning.
If people with suicide character go untreated, some will commit suicide. Let us put the SSRIs including zoloft to one side. Therapy and counselling might have saved more lives. But the warning put out by Health Canada was vague. It did not instruct doctors or their patients how to react. Were they to stop prescribing or taking zoloft? When some parents are ashamed of their children’s illness, it can be difficult to get them to bring their children for treatment. Put out a vague warning with no specific recommendation on how to react, and prejudices are confirmed and the children are left untreated.

Ultram is said to be one of the best medication on the online market. The simple rule is that the dose should be individualised so that each person takes the smallest dose required to produce the required relief from pain. Normally, this means that patients start with a very low daily dose and slowly increase the dosage every three days until a stable and effective concentration in the blood stream is achieved.

Usually this process is very and very slow. Reason of this is that FDA often uses strange tactiks of controlling advertisement. Applying the same caution may seem somewhat unfair given the significant increase in the cost of the process. As one firm say the FDA gave notice in May 2007 that a different statistical method was to be used to analyse the clinical data. This required further testing to produce more data compatible with the new method. The disagreement about methodology affected the extent to which the company could rely only on data produced from those completing the trials. The FDA was concerned that the exclusion of data from those dropping out of the trials could skew the results on safety. But, for all the delay, the company is confident that the once-daily version of ultram is effective and safe.

Let us assume that it is approved in the US and go back to the initial statement about dosage. At present, it is easy for people to forget when a dose is due. If you take too little dose, it will cause less problems than if you take too mush. Further, if a patient is on a four-hour schedule, this means waking during the night to maintain the required blood concentration. Labopharm Inc. believes that a once-daily regime will improve compliance. The evidence from the European markets on this point is encouraging.

Ambien is a sleep medication that can only be prescribed by your healthcare provider. When you talk to your doctor, he or she can determine what your exact needs are. Whether you are trying to regain your sleep pattern after extended traveling or you simply cannot get the sleep you know your body needs, having the right sleep aide will allow you to get yourself back on track. You should know that you should have at least 8 hours of sleep to give to your medication as this will give you the solid sleep you want.

Much of it has been thought to be something that an individual can just “get over”. It is common knowledge that you can’t overcome insomnia alone. After you’ve tried to get up and walk around, exercise and eat right, drink warm milk, you have to wonder:what is out there to help? Well now that there is Ambien, those who suffer from the countless nights of no sleep can finally find relief. After you’ve experienced trying everything else, Ambien.

You can feel strange first several times you use this medication. For those who believe that they can regain their sleep pattern all on their own, they may be fighting an uphill battle. For the most part, having a sleep aide like Ambien and the guidelines that your physician provides you when using Ambien is the best way to get your sleep. Now is the time to take control of your life and you can do so with the help of Ambien.

Cialis, Viagra and Levitra are prescription medications of alike mechanisms aimed to strengthen natural reaction on sexual excitement of a mans organism, which intensify blood afflux to the penis, and provide a full erection.

Viagra is the most well-known ED medication.

Generic Viagra, presented in our pharmacy, is a full analogue to Brand Viagra in terms of its action and  chemical composition, intended to intensify the potency in men suffering from erection disorders, including the ultimate form of an erectile dysfunction (ED) - impotence. This disorder is specified by absence of an erection sufficient to carry out a sexual intercourse, or by an impaired erection.  ED may be invoked by various reasons both of a psychological character and a physiological one. According to the results of clinical tests the application of Viagra is effective in about 80 per cent of the cases of erectile dysfunction. Viagra provides blood afflux to the penis and prevents its reflux, in doing so the erection does not arise involuntary, but only in response to sexual excitement. It means that Viagra does not substitute natural processes of sexual excitement, but only intensifies them.  Moreover, Viagra makes pathway to oxytocin in the brain, a hormone which awakes romantic feelings. Viagra does not influence mans reproductive functions. 

Levitra is the safest medication.

Medication Levitra is the newest product, an innovation in the field of ED medications. In some cases it is not recommended to cure erectile dysfunction with the use of such medicines as Cialis and Viagra, for instance, in patients with  diabetes and cardio ischemia. At the same time, among the factors which in the first place lead to the progression of erectile dysfunction, one may attribute cardio-vascular diseases, smoking, fatness and diabetes. Moreover, Levitra is an extraordinary efficient medication, its initial dosage is only one fifth of that of Viagra, and so it reduces the risk of side effects and their intensity. Thus, one may say that Levitra has a larger safety profile, especially for men suffering from cardio-vascular diseases and diabetes. Also Levitra is three times superior Viagra in terms of duration of the effect, providing the readiness of men to a sexual intercourse during 12 hours after intake. 

Cialis is the most efficient medication.

Generic Cialis is a full analogue to Brand Cialis in terms of chemical composition and action, intended to intensify the potency in men suffering from ED. Cialis provides blood afflux to the penis, in doing so the erection does not arise involuntary, but only in response to sexual excitement. It means that Viagra does not substitute natural processes of sexual excitement, but only intensifies them. Cialis does not influence mans reproductive functions. The main difference of Cialis from Viagra, in the first place, is a less quantity of minimal necessary active substance. If for Viagra the minimum necessary dose is 25 mg. (in most cases the minimum necessary dose of the medication is 50 mg), for Cialis it is 20 mg. This difference provides lesser risks of side effects and their less intensity. One more critical difference of Cialis from Viagra and Levitra is a prolonged time of effectiveness. If effectiveness time of Viagra is 4 hours, that of Levitra is 12 hours, whereas the effectiveness time of Cialis is 36 hours.

Did you see the news last December that Terry Pratchett has Alzheimer’s. He is only 59. When I was younger, we used to congratulate anyone who approached their sixtieth birthday without dying. Now, with the improvements in diet and medical science, we all expect to live a lot longer. This is all a little double-edged.

As I grow older, one of the things I fear is that my mind may die before my body. There is nothing more depressing than watching your own personality disappear, leaving nothing but apparently immortal flesh behind. As an interested spectator, I have had relatives who sat or lay like vegetables in nursing homes for several years while we all waited for them to die. Which makes the anecdotal point that depression affects many when they are diagnosed with Alzheimer’s. As the disease progresses, depression also spreads to the immediate carers in the family, other relatives and friends. Perhaps we carers should all be reaching for the Zoloft.

The clinical evidence suggests that about 25% of people with Alzheimer’s suffer persistent depression, although there are no formal studies that map the relationship between the two. What we can say is that, when it arises, depression significantly affects the quality of life for all involved. Patients can be more quickly shuffled off into a nursing home or there is a risk of suicide by any of those involved.

The research links serotonin and the neurotransmitter systems with depression, but the evidence for the use of Zoloft and other Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment of those with Alzheimer’s has been patchy. Part of the problem is in assembling statistically significant sized groups of participants with broadly similar levels of symptoms (from mild to demented). The other problem is money. In the UK, there are about 700,000 people with Alzheimer’s, but only £10 per patient is spent each year on research into the disease — less than 5% of the amount spent on research into cancer. However, in Arch Gen Psychiatry, Jul 2003 there was a slightly better attempt made to test the safety and effectiveness of Zoloft for both the person with Alzheimer’s and, indirectly, for the caregivers. This was a 12-week randomised, placebo-controlled trial.

The first piece of good news was that the intellectual level of people diagnosed with Alzheimer’s who received Zoloft remained relatively stable, whereas the placebo group declined. However, there is a problem in that the evaluations were based on the caregivers’ reports and their expectations (and hopes) may have played a part in skewing the results. Nevertheless, the finding is interesting. There were few side effects in those who took the Zoloft.

The second piece of good news is that Zoloft did reduce the depression experienced by the Alzheimer’s patient and this significantly relieved caregiver distress. Given that private care is usually of a better quality than institutional care, this is a major step forward. It also has significantly economic implications for the state that may otherwise have to subsidise long-term care in an institutional home or hospital. Those receiving the Zoloft were less likely to wander around, or become agitated or aggressive. If confirmed in continuing trials, such behavioural improvements will mean that caregivers can continue to give personalised and individualised care for longer. This may slow the loss of personality and lessen the burden of guilt when the patient is finally sent into an institution.

So should all of us Baby Boomers reach for the Zoloft if we feel ourselves slipping away or bulk buy Zoloft for distribution to our potential caregivers? Well, this research is simply a useful indicator. There are many difficulties in relying on one set of findings to give generalised advice. I suppose that is the benefit of continuing research. So long as it delivers good news before we die, of course.